Investigation of Immunohistochemical Expression of Programmed Death-Ligand 1 (PD-L1) in Female Mammary Carcinoma and its Correlation with the Extent of Stromal Tumour Infiltrating LymphocytesCorrespondence Address :
Passant Essam Eldin Shibel,
6 El Sahaba Square, Mossadaq Street, Dokki, Giza, Egypt.
Introduction: Breast Cancer (BC) is the most common type of cancer among women worldwide and a leading cause of cancer related deaths. Based on insight into immune system/cancer interactions, cancer immunotherapy strategies have been developed. Of these strategies, immune checkpoints regulators are among the most important. Programmed Death Ligand 1 (PD-L1) is one of the 2 ligands of Programmed Death-1 (PD-1); an important immune checkpoint regulator. Clinical trials using PD-L1 antibodies have shown efficacy in various cancers. Some of these antibodies have received Food and Drug Administration (FDA) approval for clinical use.
Aim: Detection of Immunohistochemical (IHC) expression of PD-L1 by Tumour Cells (TC) and stromal Tumour Infiltrating Lymphocytes (TILs) in female BC, as well as, correlation of this expression with the pathologic parameters of the tumours.
Materials and Methods: One hundred BC tissue sections were collected from mastectomy specimens. IHC expression of PD-L1 was investigated in TC and TILs. Correlation of PD-L1 expression with the tumours pathologic parameters was performed using Statistical Package of Social Science (SPSS) Software program, version 25.0.
Results: TC PD-L1 expression was detected in 61% of cases and showed statistically significant correlation with higher tumour grade, higher prognostic stage, Estrogen receptor negativity, Human Epidermal Growth Factor Receptor Type 2 (HER2) enriched molecular subtype and LVI (p-value <0.05). TILs PD-L1 expression was detected in 55% of cases and showed statistically significant correlation with higher tumour grade, higher prognostic stage, Estrogen and Progesterone receptor negativity, HER2 overexpression, higher Ki-67 index, triple negative molecular subtype and higher stromal TILs (p-value <0.05).
Conclusion: The present results supported PD-L1 expression in BC by both TC and TILs, with higher expression in subset of tumours that are high grade, TILs rich and lacking hormone receptors, highlighting them as candidates for anti-PD-1/PD-L1 therapy.
Breast carcinoma, Programed death ligand 1, Tumor cells, Tumor infiltrating lymphocytes
Passant Essam Eldin Shibel, Hanan Soliman Abdelhamid, Somia Abdulatif Mahmoud Soliman, Samia Mohamed Gabal. INVESTIGATION OF IMMUNOHISTOCHEMICAL EXPRESSION OF PROGRAMMED DEATH-LIGAND 1 (PD-L1) IN FEMALE MAMMARY CARCINOMA AND ITS CORRELATION WITH THE EXTENT OF STROMAL TUMOUR INFILTRATING LYMPHOCYTES. Journal of Clinical and Diagnostic Research [serial online] 2019 September [cited: 2019 Sep 16 ]; 13:EC11-EC17. Available from
Date of Submission: Jun 14, 2019
Date of Peer Review: Jun 27, 2019
Date of Acceptance: Jul 31, 2019
Date of Publishing: Sep 01, 2019
FINANCIAL OR OTHER COMPETING INTERESTS: None.
- Emerging Sources Citation Index (Web of Science, thomsonreuters)
- Index Copernicus ICV 2017: 134.54
- Academic Search Complete Database
- Directory of Open Access Journals (DOAJ)
- Google Scholar
- HINARI Access to Research in Health Programme
- Indian Science Abstracts (ISA)
- Journal seek Database
- Popline (reproductive health literature)